Jeronselvein, a company specializing in the production of prescription pharmaceuticals, announced on October 27 that it has signed a memorandum of understanding (MOU) with the Korean Academy of Implant Dentistry (KAID) to promote academic advancement and clinical education in the field of dental implants.
This agreement aims to drive innovation in implant treatment and the development of patient-centered medical technologies by supporting research and development in dental regenerative medicine and implants, sharing clinical data, expanding regenerative medicine approaches in clinical settings, and strengthening the capabilities of dental professionals.
Jeronselvein, a leading company in regenerative medicine based on polydeoxyribonucleotide (PDRN), plans to facilitate academic exchange within the dental community by organizing hands-on seminars and inviting lectures on PDRN at academic conferences and training sessions hosted by the academy.
Under the agreement, Jeronselvein will jointly conduct research with the Korean Academy of Implant Dentistry to promote bone tissue regeneration, utilizing its proprietary patented technology, 'Prism Technology Nano PDRN', for PDRN extraction and cell regeneration platforms.
The two parties will carry out research projects on topics such as regeneration of peri-implant bone defects, enhancement of osseointegration, and verification of the combined effects of bone graft materials and PDRN. These efforts are expected to introduce a new treatment paradigm in the field of dental regenerative medicine.
Jeronselvein CEO Kim Deokgyu stated, "This MOU will serve as an opportunity for Jeronselvein and the Korean Academy of Implant Dentistry to become a model case of industry-academia collaboration," adding, "Through close cooperation with the academy, we expect to strengthen our position in the dental regenerative treatment market and enhance our brand credibility."
He further added, "Jeronselvein's PDRN technology, combined with the expertise of the Korean Academy of Implant Dentistry, will set a new standard in the domestic dental regenerative medicine field and serve as a turning point to elevate both academic and industrial competitiveness."
Kim Sungmin, President of the Korean Academy of Implant Dentistry, commented, "This agreement is a meaningful milestone in expanding the possibilities of regenerative medicine approaches in the field of dental implants," and added, "If the academy's clinical experience is combined with Jeronselvein's PDRN technology, it is expected to greatly improve the quality of patient care in dental clinical settings and contribute significantly to the advancement of dental regenerative medicine in Korea."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
